Preview

Медицинский Совет

Расширенный поиск

РОЛЬ ПРОБИОТИКОВ В ЛЕЧЕНИИ HELICOBACTER PYLORI-АССОЦИИРОВАННЫХ ЗАБОЛЕВАНИЙ

https://doi.org/10.21518/2079-701X-2017-5-80-84

Полный текст:

Аннотация

Helicobacterpylori (Hр) является распространенным  грамотрицательным,  жгутиковым спиральным  микроорганизмом, инфицирующим слизистую оболочку желудка. В 1994  г. Международное агенство по изучению рака включило  H. pylori в список канцерогенов первой группы. Терапевтические варианты лечения инфекции, вызванной бактерией H. pylori, направленные на полное ее уничтожение,  включают в себя различные сочетания ингибиторов протонного насоса совместно с двумя или тремя антибиотиками. Такой комплексный подход обладает по своему существу высокими рисками возникновения побочных эффектов и несоблюдения лечения. Согласно Маастрихтскому соглашению с целью снижения риска побочных эффектов на микробиоценоз ЖКТ и повышения эффективности эрадикации целесообразно добавление пробиотиков в схемы эрадикации. Доказана способность некоторых штаммов пробиотиков вызывать эрадикацию при монотерапии. Тем не менее при анализе данных в подгруппах  лишь некоторые штаммы сохраняли  клиническую значимость, в т. ч. различные штаммы рода Lactobacillus. Штамм LасtobacillusreuteriDSMZ17648 (субстанция Pylopass, входит в состав торгового наименования Хелинорм) показывает снижение уровня колонизации  H. pylori и может использоваться в схеме эрадикационной терапии с целью повышения ее эффективности и безопасности.

Об авторах

Е. Ю. Плотникова
Кемеровский государственный медицинский университет Минздрава РФ
Россия

Доктор медицинских наук, профессор



Т. Ю. Грачева
Кемеровский государственный медицинский университет Минздрава РФ
Россия

Доктор медицинских наук, профессор



Список литературы

1. Boltin D. Probiotics in Helicobacter pyloriinduced peptic ulcer disease. Clinical gastroenterology, 2016, 30(1): 99–109.

2. Ianiro G, Molina-Infante J, and Gasbarrini A. Gastric microbiota. Helicobacter, 2015, 20: 68–71.

3. Delgado S, Cabrera-Rubio R, Mira A, Suárez A and Mayo B. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol., 2013, 65: 763–772.

4. Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P and Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One, 2008, 3: e2836.

5. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA, 2006, 103: 732–737.

6. Li X, Wong GL, To K, Wong VW, Lai LH, Chow DK et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One, 2009, 4(e7985).

7. Saxelin M, Tynkkynen S, Mattila-Sandholm T and de Vos, W.M. Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol, 2005, 16: 204–211.

8. Saha A, Hammond CE, Beeson C, Peek RM, and Smolka AJ. Helicobacter pylori represses proton pump expression and inhibits acid secretion in human gastric mucosa. Gut, 2010, 59: 874–881.

9. Schepp W, Dehne K, Herrmuth H, Pfeffer K and Prinz C. Identification and functional importance of IL-1 receptors on rat parietal cells. Am J Physiol, 1998, 275: G1094–G1105.

10. Celli JP, Turner BS, Afdhal NH, Keates S, Ghiran I, Kelly CP et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci USA, 2009, 106: 1432.

11. Bovenkamp Van de, Jeroen HB, Mahdavi J, Korteland-Van Male AM, Büller HA, Einerhand AWC et al. The MUC5AC glycoprotein is the primary receptor for Helicobacter pylori in the human stomach. Helicobacter, 2003, 8: 521–532.

12. Tanaka S, Mizuno M, Maga T, Yoshinaga F, Tomoda J, Nasu J et al. H. pylori decreases gastric mucin synthesis via inhibition of galactosyltransferase. Hepatogastroenterology, 2003, 50: 1739–1742.

13. Peterson AJ, Menheniott TR, O’Connor L, Walduck AK, Fox JG, Kawakami K et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology, 2010, 139: 2005–2017.

14. Nakayama M, Kimura M, Wada A, Yahiro K, Ogushi K, Niidome T et al. Helicobacter pylori VacA activates the p38/activating transcription factor 2-mediated signal pathway in AZ-521 cells. J Biol Chem., 2004, 279: 7024–7028.

15. Guruge JL, Falk PG, Lorens RG, Dans M, With НР, Blaser MJ, Berg DE, Gordon JI. Epithelial attachment alters the outcome of Helicobacter pylori infection. Proc. Nalt. Acad. Sci. USA., 1998, Mar, 31, 95(7): 3925-30.

16. Yang Y, Chuang C, Yang H, Lu C and Sheu B. Lactobacillus acidophilus ameliorates H. pyloriinduced gastric inflammation by inactivating the Smad7 and NFκB pathways. BMC Microbiol., 2012, 12: 38.

17. Yu H, Liu W, Chang Z, Shen H, He L, Wang S et al. Probiotic BIFICO cocktail ameliorates Helicobacter pylori induced gastritis. World J Gastroenterol., 2015, 21: 6561–6571.

18. Keersmaecker De Sigrid CJ, Verhoeven TLA, Desair J, Marchal K, Vanderleyden J et al. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol Lett., 2006, 259: 89–96.

19. Cunningham-Rundles S, Ahrne S, Bengmark S, Johann-Liang R, Marshall F, Metakis L et al. Probiotics and immune response. Am J Gastroenterol., 2000, 95: S22–5.

20. Mack DR, Michail S, Wei S, McDougall L and Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol., 1999, 276: G941–G950.

21. Coconnier MH, Lievin V, Hemery E and Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol., 1998, 64: 4573–4580.

22. Valeur N, Engel P, Carbajal N, Connolly E and Ladefoged K. Colonization and Immunomodulation by lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol., 2004, 70: 1176–1181.

23. Felley CP, Corthesy-Theulaz I, Rivero JL, Sipponen P, Kaufmann M, Bauerfeind P et al. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol., 2001, 13: 25–29.

24. Conway PL and Kjelleberg S. Protein-mediated adhesion of Lactobacillus fermentum strain 737 to mouse stomach squamous epithelium. J Gen Microbiol., 1989, 135: 1175–1186.

25. Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, and Versalovic J. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe, 2008, 14: 166–171.

26. Aiba Y, Nakano Y, Koga Y, Takahashi K and Komatsu Y. A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiologyopen, 2015, 4: 465–474.

27. Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis, 2008, 40: 650–658.

28. Felley CP, Corthesy-Theulaz I, Rivero JL, Sipponen P, Kaufmann M, Bauerfeind P et al. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol, 2001, 13: 25–29.

29. Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter, 2008, 13: 127–134.

30. Pantoflickova D, Corthésy-Theulaz I, Dorta G, Stolte M, Isler P, Rochat F et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther., 2003, 18: 805–813.

31. Tong JL, Ran ZH, Shen J, Zhang CX and Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther., 2007, 25: 155–168.

32. Zou J, Dong J and Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter, 2009, 14: 97–107.

33. Sachdeva A and Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol., 2009, 21: 45–53.

34. Szajewska H, Horvath A and Piwowarczyk A. Metaanalysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther., 2010, 32: 1069–1079.

35. Wang Z, Gao Q and Fang J. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol., 2013, 47: 25–32.

36. Zheng X, Lyu L and Mei Z. Lactobacilluscontaining probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig., 2013, 105: 445–453.

37. Li S, Huang X, Sui J, Chen S, Xie Y, Deng Y et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr., 2014, 173: 153–161.

38. Dang Y, Reinhardt JD, Zhou X and Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a metaanalysis. PLoS One, 2014, 9: e111030.

39. Zhu R, Chen K, Zheng Y, Zhang H, Wang J, Xia Y et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol., 2014, 20: 18013–18021.

40. Zhang M, Qian W, Qin Y, He J and Zhou Y. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol., 2015, 21: 4345–4357.

41. Gong Y, Li Y and Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med., 2015, 8: 6530–6543

42. Tyagi AK, Prasad S. Commentary: Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front. Microbiol., 2014, 5: 766.

43. Li B, Threapleton DE, Wang J, Xu J, Yuan J, Zhang C et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ, 2015, 351(h4052).

44. Dore MP, Cuccu M, Pes GM, Manca A, Graham DY. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med., 2014, 9(6): 649-54.

45. Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a doubleblind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol., 2014, 7(1): 4-13.

46. Lee YC, Chiang TH, Chou CK et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 150(5): 1113-24.

47. Mehling H, Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans. Nutrients, 2013, 5(8): 3062-3073.

48. Holz C, Busjahn A, Mehling H et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob Proteins, 2015, 7(2): 91-100.

49. Ford AC, Forman D, Hunt R, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev., 2015(7):Cd005583.

50. Плотникова Е.Ю., Золотухина В.Н., Краснов О.А. Новые возможности адьювантной антихеликобактерной терапии. Лечащий врач, 2015, 3: 76-81.

51. Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б., Ким В.А., Быстровская Е.В., Шишин К. В. Эффективность и безопасность Lactobacillus reuteri DSMZ17648 у инфицированных Helicobacter pylori. Лечащий врач, 2016, 5: 106-112.

52. Успенский Ю.П., Фоминых Ю.А., Иванов С.В., Менакер И.О. Эволюция в эрадикационной терапии НР-ассоциированных заболеваний. Выход за рамки стандартов? РМЖ. Гастроэнтерология, 2016, 17: 1144-1152.

53. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht V/ Florence Consensus Report. Gut, 2016, 0: 1–24.

54. Н.В. Захарова, И.Г. Бакулин, В.И. Симаненков, А.А. Маслыгина. Обзор рекомендаций пятого Маахстрихтского/Флорентийского консенсуса по диагностике и лечению инфекции Helicobacter Pylori. Фарматека. Гастроэнтерология, 2016, 2: 8-27.


Для цитирования:


Плотникова Е.Ю., Грачева Т.Ю. РОЛЬ ПРОБИОТИКОВ В ЛЕЧЕНИИ HELICOBACTER PYLORI-АССОЦИИРОВАННЫХ ЗАБОЛЕВАНИЙ. Медицинский Совет. 2017;(5):80-84. https://doi.org/10.21518/2079-701X-2017-5-80-84

For citation:


Plotnikova E.Y., Gracheva T.Y. THE ROLE OF PROBIOTICS IN THE TREATMENT OF HELICOBACTER PYLORI ASSOCIATED DISEASES. Medical Council. 2017;(5):80-84. (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-80-84

Просмотров: 1795


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)